BRWA
GNMX

B. Riley Wealth Advisors’s Aevi Genomic Medicine Inc GNMX Stock Holding History

B. Riley Wealth Advisors’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-2,000
Closed -$10 – 2276
2014
Q4 		$10 Buy
+2,000
New +$9.88K ﹤0.01% 2896
2014
Q3 		– Sell
-2,000
Closed -$15.5K – 2128
2014
Q2 		$15.5K Buy
+2,000
New +$14.1K ﹤0.01% 1585

Other funds holding GNMX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

B. Riley Wealth Advisors's GNMX Position: Q1 2015 in Review

B. Riley Wealth Advisors sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2015, closing a stake of 2,000 shares — an estimated $10 sold.

B. Riley Wealth Advisors first reported a position in GNMX in Q2 2014 and held it in 2 quarters. The position peaked at $15.5K in Q2 2014. 43 funds tracked by Wall St. Rank hold GNMX as of Q1 2015.

  • B. Riley Wealth Advisors reported no remaining Aevi Genomic Medicine Inc position as of Q1 2015 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 2,000 Aevi Genomic Medicine Inc shares in Q1 2015, an estimated $10.
  • B. Riley Wealth Advisors first reported a position in Aevi Genomic Medicine Inc in Q2 2014 and held it in 2 quarters.
  • B. Riley Wealth Advisors's Aevi Genomic Medicine Inc position peaked at $15.5K in Q2 2014.
  • 43 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2015.

Based on B. Riley Wealth Advisors's 13F filing for Q1 2015, filed 14 May 2015.